Onyx ONE trial: a new option in patients at high risk of bleeding

Abstract

INTRODUCTION Due to the commotion caused by the growing number of late thrombosis after drug-eluting stents implantation back in 2005,1 1 year courses of dual antiplatelet therapy (DAPT) were recommended after the implants. The lower rate of this complication thanks to improved designs of the device has made it possible to shorten these courses. The shortest courses of DAPT are still under discussion2-4 (figure 1), yet 1-month courses of DAPT with further withdrawal of 1 of the 2 drugs has been agreed on. However, most 1-month DAPT studies have been conducted with low-risk patients5,6 or have focused on patients with stable coronary artery disease.7